Atrayee Bhattacharya

Atrayee Bhattacharya

Auto-generated profile, based on publicly available information

Atrayee Bhattacharya

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
NYNami Yamashita
Nami Yamashita
YMYoshihiro Morimoto
Yoshihiro Morimoto
Atsushi FushimiAtsushi Fushimi
Atsushi Fushimi
RARehan Ahmad
Rehan Ahmad
ABAtrayee Bhattacharya
Atrayee Bhattacharya
DKDonald Kufe
Donald Kufe
The polybromo-1 (PBRM1) chromatin-targeting subunit of the SWI/SNF PBAF chromatin remodeling complex drives DNA damage resistance and immune evasion in certain cancer cells through mechanisms that remain unclear. STAT1 and IRF1 are essential effectors of type I and II IFN pathways. Here, we report that MUC1-C is necessary for PBRM1 expression and that it forms a nuclear complex with PBRM1 in triple-negative breast cancer (TNBC) cells. Analysis of global transcriptional (RNA-seq) and chromatin accessibility (ATAC-seq) profiles further demonstrated that MUC1-C and PBRM1 drive STAT1 and IRF1 expression by increasing chromatin accessibility of promoter-like signatures (PLS) on their respective genes. We also found that MUC1-C, PBRM1, and IRF1 increase the expression and chromatin accessibility on PLSs of the (i) type II IFN pathway IDO1 and WARS genes and (ii) type I IFN pathway RIG-I, MDA5, and ISG15 genes that collectively contribute to DNA damage resistance and immune evasion. In support of these results, targeting MUC1-C in wild-type BRCA TNBC cells enhanced carboplatin-induced DNA damage and the loss of self-renewal capacity. In addition, MUC1-C was necessary for DNA damage resistance, self-renewal, and tumorigenicity in olaparib-resistant BRCA1-mutant TNBC cells. Analysis of TNBC tumors corroborated that (i) MUC1 and PBRM1 are associated with decreased responsiveness to chemotherapy and (ii) MUC1-C expression is associated with the depletion of tumor-infiltrating lymphocytes (TIL). These findings demonstrate that MUC1-C activates PBRM1, and thereby chromatin remodeling of IFN-stimulated genes that promote chronic inflammation, DNA damage resistance, and immune evasion. Implications: MUC1-C is necessary for PBRM1-driven chromatin remodeling in chronic activation of IFN pathway genes that promote DNA damage resistance and immunosuppression.

1 February 2022 in OncoImmunology
Verified
Journal Article
Open access
MHMasayuki Hagiwara
Masayuki Hagiwara
Atsushi FushimiAtsushi Fushimi
Atsushi Fushimi
ABAtrayee Bhattacharya
Atrayee Bhattacharya
NYNami Yamashita
Nami Yamashita
YMYoshihiro Morimoto
Yoshihiro Morimoto
DKDonald Kufe
Donald Kufe
The oncogenic MUC1-C protein drives dedifferentiation of castrate resistant prostate cancer (CRPC) cells in association with chromatin remodeling. The present work demonstrates that MUC1-C is necessary for expression of IFNGR1 and activation of the type II interferon-gamma (IFN-γ) pathway. We show that MUC1-C→ARID1A/BAF signaling induces IFNGR1 transcription and that MUC1-C-induced activation of the NuRD complex suppresses FBXW7 in stabilizing the IFNGR1 protein. MUC1-C and NuRD were also necessary for expression of the downstream STAT1 and IRF1 transcription factors. We further demonstrate that MUC1-C and PBRM1/PBAF are necessary for IRF1-induced expression of (i) IDO1, WARS and PTGES, which metabolically suppress the immune tumor microenvironment (TME), and (ii) the ISG15 and SERPINB9 inhibitors of T cell function. Of translational relevance, we show that MUC1 associates with expression of IFNGR1, STAT1 and IRF1, as well as the downstream IDO1, WARS, PTGES, ISG15 and SERPINB9 immunosuppressive effectors in CRPC tumors. Analyses of scRNA-seq data further demonstrate that MUC1 correlates with cancer stem cell (CSC) and IFN gene signatures across CRPC cells. Consistent with these results, MUC1 associates with immune cell-depleted “cold” CRPC TMEs. These findings demonstrate that MUC1-C integrates chronic activation of the type II IFN-γ pathway and induction of chromatin remodeling complexes in linking the CSC state with immune evasion.

14 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
HOHiroki Ozawa
Hiroki Ozawa
KTKazuki Takahashi
Kazuki Takahashi
TMTomoki Motegi
Tomoki Motegi
JJJustine Jacobi
Justine Jacobi
ABAtrayee Bhattarchya
Atrayee Bhattarchya
DKDonald Kufe
Donald Kufe
Purpose: Treatment of pancreatic ductal adenocarcinoma (PDAC) has been advanced by the development of KRAS inhibitors. Despite this progress, PDAC invariably develop resistance to these agents through multiple mechanisms. In this study, we investigated the role of the oncogenic MUC1-C (M1C) protein in mediating the resistance of PDAC cells to KRAS inhibition. Experimental Design: Three PDAC KRAS G12D–mutant cell lines, as well as patient-derived KRAS inhibitor–resistant organoids and patient-derived xenograft models, were investigated in these studies. An anti-M1C antibody–drug conjugate (ADC) was evaluated for in vitro and in vivo activity. Tumors from patients with PDAC were studied by single-cell RNA sequencing and IHC staining. Results: The MUC1 gene is upregulated in PDAC KRAS G12D–mutant tumors. We report that treatment of PDAC cells with the KRAS G12D inhibitor MRTX1133 is associated with the induction of the M1C protein. Mechanistically, KRAS G12D inhibition induces M1C by activation of an M1C/NF-κB p65 autoinductive pathway. Our results further demonstrate that M1C drives resistance to MRTX1133 by activating the inflammatory IFN type I pathway. Targeting M1C genetically and pharmacologically thereby reverses MRTX1133 resistance and is synergistic in combination with MRTX1133 treatment. Of translational significance, we demonstrate that an anti-M1C ADC is highly effective against MRTX1133-resistant PDAC KRAS G12D cell lines and patient-derived organoid and patient-derived xenograft models. Conclusions: These findings demonstrate that M1C confers resistance of PDAC to KRAS G12D inhibition and identify M1C as a potential target for ADC treatment of patients with PDAC who are refractory to KRAS inhibitors.

15 April 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
ANAyako Nakashoji
Ayako Nakashoji
NHNaoki Haratake
Naoki Haratake
ABAtrayee Bhattacharya
Atrayee Bhattacharya
WMWeipu Mao
Weipu Mao
KXKangjie Xu
Kangjie Xu
DKDonald Kufe
Donald Kufe
The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCCs). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCCs). Studies of HNSCC cell lines demonstrate that the MUC1-C subunit regulates expression of (i) RIG-I and MDA5 pattern recognition receptors, (ii) STAT1 and interferon (IFN) regulatory factors, and (iii) downstream IFN-stimulated genes (ISGs). MUC1-C integrates chronic activation of the STAT1 inflammatory pathway with induction of the ∆Np63 and SOX2 genes that are aberrantly expressed in HNSCCs. In extending those dependencies, we demonstrate that MUC1-C is necessary for NOTCH3 expression, self-renewal capacity and tumorigenicity. The findings that MUC1 associates with ∆Np63, SOX2 and NOTCH3 expression by scRNA-seq analysis further indicate that MUC1-C drives the HNSCC stem cell state and is a target for suppressing HNSCC progression.

3 April 2023
Verified
Other
Open access
NYNami Yamashita
Nami Yamashita
YMYoshihiro Morimoto
Yoshihiro Morimoto
Atsushi FushimiAtsushi Fushimi
Atsushi Fushimi
RARehan Ahmad
Rehan Ahmad
ABAtrayee Bhattacharya
Atrayee Bhattacharya
DKDonald Kufe
Donald Kufe
S1. Silencing MUC1-C downregulates IRF1 expression in TNBC cells. S2. Effects of silencing MUC1-C on TNBC cells. S3. MUC1-C is necessary for PBRM1 expression A and B. S4. MUC1-C forms a direct complex with IRF1 that activates type I and II ISGs. S5. Common genes regulated in cells silenced for MUC1, IRF1, and PBRM1. S6. Silencing MUC1-C, IRF1, and PBRM1 downregulated IDO1 and WARS in TNBC cells. S7. Silencing of MUC1-C, IRF1, and PBRM1 downregulates RIG-I and MDA5 in TNBC cells. S8. Silencing MUC1-C, IRF1, and PBRM1 downregulates ISG15 expression in TNBC cells. S9. Effects of silencing IRF1 and PBRM1 on BT-549 mammosphere formation and GO-203 treatment on the viability of olaparib-resistant MDA-MB-436RR cells. Table S1. Primers used for qRT-PCR. Table S2. Primers used for ChIP-qPCR and DNase I chromatin accessibility assays. Table S3. Common downregulated 196 DEGs in BT-549 cells with silencing of MUC1, IRF1, and PBRM1. Table S4. Overlapping IFN-pathway genes downregulated in cells with MUC1-C, PBRM1, and IRF1 silencing.

27 November 2025
Verified
Other
Open access
NYNami Yamashita
Nami Yamashita
YMYoshihiro Morimoto
Yoshihiro Morimoto
Atsushi FushimiAtsushi Fushimi
Atsushi Fushimi
RARehan Ahmad
Rehan Ahmad
ABAtrayee Bhattacharya
Atrayee Bhattacharya
DKDonald Kufe
Donald Kufe
MUC1-C/PBRM1/IRF1 complexes induce chromatin accessibility and expression of the IDO1 and WARS genes. A, Candidate pathway enrichment plot for the IFNG response and tryptophan metabolism in BT-549 cells silenced for MUC1-C, IRF1, and PBRM1. B, Schema of the IDO1 gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti-MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the IDO1 PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). C, Schema of the WARS gene with localization of a PLS upstream to the TSS. Soluble chromatin from BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with a control IgG, anti–MUC1-C, anti-IRF1, and anti-PBRM1. The DNA samples were amplified by qPCR with primers for the WARS PLS region. The results (mean ± SD and individual values) are expressed as relative fold enrichment as compared with that obtained with IgG (assigned a value of 1). D and E, Genome browser snapshots of ATAC-seq data from the IDO1 (D) and WARS (E) PLS regions in BT-549/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days (left). Chromatin was analyzed for accessibility by nuclease digestion (right). The results are expressed as the percentage of undigested chromatin (mean ± SD and individual values). F and G, Chromatin from BT-549/CshRNA and BT-549/PBRM1shRNA cells was analyzed for accessibility of the IDO1 (F) and WARS (G) PLS regions by nuclease digestion. The results are expressed as the percentage of undigested chromatin (mean±SD and individual values). *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.